Keytruda

Keytruda
Name	Keytruda
Tradename	Keytruda
Drug name	pembrolizumab
Routes of administration	Intravenous infusion
ATC prefix	L01
ATC suffix	XC18
Legal status	Prescription only
CAS number	1374853-91-4
KEGG	D11485

Keytruda is the trade name for pembrolizumab, a humanized monoclonal antibody used as an immune checkpoint inhibitor in oncology. Developed in the 2000s and commercialized by a multinational pharmaceutical company, it became a cornerstone therapy for multiple malignancies by targeting an immune regulatory pathway. Keytruda is administered intravenously and has been studied across diverse tumor types in multinational clinical trials and cooperative group studies.

Medical uses

Keytruda is indicated for the treatment of several malignancies including advanced or metastatic Melanoma, Non-small-cell lung cancer, Head and neck squamous cell carcinoma, Classical Hodgkin lymphoma, Urothelial carcinoma, Gastric cancer, Cervical cancer, Hepatocellular carcinoma, Renal cell carcinoma, and tumors with high microsatellite instability identified via Next-generation sequencing in accordance with oncology practice guidelines. It is used as monotherapy, in combination with platinum-based chemotherapy agents such as Cisplatin and Carboplatin, and with targeted agents like Lenvatinib in protocols endorsed by professional societies and consortiums. Indications have expanded through approvals tied to biomarker status including PD-L1 expression and tumor mutational burden criteria evaluated at tertiary cancer centers and national comprehensive cancer networks.

Mechanism of action

Pembrolizumab is a monoclonal antibody that binds to the programmed death 1 receptor on lymphocytes, interrupting interaction with ligands expressed by tumor cells and antigen-presenting cells. By blocking the PD-1/PD-L1 axis originally characterized in immunology research alongside discoveries recognized by awards in biomedical science, it reinvigorates cytotoxic T lymphocyte activity against neoplastic cells. The mechanism integrates concepts from cellular immunology and tumor microenvironment studies performed at academic institutions and research institutes.

Clinical trials and efficacy

Pivotal randomized controlled trials and multicenter phase II/III studies conducted by cooperative groups and pharmaceutical sponsors established efficacy across tumor types. Key phase III trials compared pembrolizumab to standard-of-care chemotherapies such as Paclitaxel-based regimens and demonstrated improved overall survival and durable response rates in subsets defined by PD-L1 expression or deficient mismatch repair status identified at university hospitals. Long-term follow-up and pooled analyses from networks and registries have informed meta-analyses and guideline updates by organizations in oncology.

Adverse effects and safety

Immune-mediated adverse effects are characteristic, including inflammatory events affecting organs such as the skin, lungs, colon, liver, endocrine glands, and kidneys; these events require surveillance and management protocols used in tertiary care centers. Serious events like pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis necessitate immunosuppression per guidelines from professional societies. Safety data accumulated from post-marketing surveillance, pharmacovigilance programs, and regulatory agency reviews informs risk mitigation strategies in outpatient oncology clinics and infusion centers.

Dosage and administration

Pembrolizumab is administered as an intravenous infusion at weight-based or fixed dosing schedules determined by labeling decisions and pivotal study protocols. Infusion intervals and dose modifications reflect findings from clinical pharmacology studies and are applied in oncology departments, cancer centers, and clinical trial sites. Pre-infusion evaluation, monitoring during administration, and management of infusion reactions follow institutional policies and specialty society recommendations.

Regulatory approval and availability

Regulatory approvals were granted by national agencies following review of clinical trial data and post-marketing commitments; decisions were informed by advisory committee evaluations and international regulatory harmonization efforts. Availability varies by country and is influenced by pricing negotiations, reimbursement determinations by health technology assessment bodies, and inclusion in national formularies and oncology treatment pathways.

Pharmacology and chemistry

Pembrolizumab is a humanized IgG4 kappa monoclonal antibody produced using recombinant DNA technologies in mammalian cell expression systems. Its pharmacokinetic profile includes a distribution phase and a long elimination half-life consistent with monoclonal antibodies used in oncology. Biochemical characterization, manufacturing controls, and analytical methods are described in regulatory dossiers submitted to agencies and evaluated by scientific reviewers.

Category:Monoclonal antibodies Category:Antineoplastic drugs